今日，加科思药业在第五届RAS倡议研讨会上，以壁报的形式公布了旗下SHP2抑制剂JAB-3312和KRAS ...

Growth inhibition by TAS102 plus regorafenib occurs in xenografted tumors regardless of p53, KRAS or BRAF mutations, although ...

Figure 2. Model for tracking loss of p53 in developing tumors. The model is engineered such that pancreatic epithelial cells become Kras G12D, p53-/+ and express mKate (red) and GFP when mice are ...

【导读】LACTB在几种肿瘤中被认为是肿瘤抑制因子。然而，初步研究表明，在骨肉瘤中，LACTB过表达，预示预后不良。9月26日，中山大学尹军强教授研究团队在期刊《Advanced Science》上发表了研究论文，题为“SNPs Give LACTB ...

It causes mutations in the p53 tumor-suppressor gene as well as ras mutations, which are involved in the majority of human cancers. Aflatoxin has been shown to contaminate tobacco products.

A mutation in the KRAS gene can lead to uncontrollable cell growth and the development of cancer. Having this mutation can significantly influence the treatment and outlook of people with colon ...

加科思致力于为患者提供突破性治疗方案。公司在研项目围绕KRAS、肿瘤免疫、肿瘤代谢、P53、RB、MYC六大肿瘤信号通路布局，核心项目以全球前三为目标。加科思的实验室坐落于北京、上海和波士顿，拥有诱导变构药物发现平台 (IADDP)和免疫刺激性抗体偶联药物 (iADC)药物研发平台。

他们研发了一种抗体，它能识别突变型p53蛋白的这一片段 ... 的表面带有极低水平的癌症驱动的突变型RAS蛋白。靶向针对像RAS等癌驱动突变基因 ...

In addition, mutations are frequently detected in proteins such as p53, KRAS and APC (adenomatosis polyposis coli), which are intrinsically difficult to modulate with low-molecular-weight inhibitors.

智通财经APP讯，加科思-B(01167)发布公告，公司将在2024年第66届美国血液学会(ASH)年会上展示BET抑制剂JAB-8263的临床数据。ASH年会将于2024年12月7日至10日在美国圣迭戈举行，更多会议信息将于美国东部时间2024年1 ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...